Nurix Therapeutics, Inc. Common stock (NRIX) Stock
NASDAQ · NRIX
25.44
Fundamentals
Market cap
$2.64B
Price / Earnings ratio
-7.8x
Price / Sales ratio
72.0x
Price / Book ratio
6.6x
Return on assets
-0.5%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.0%
Debt / Equity ratio
N/A
Latest news
About Nurix Therapeutics, Inc. Common stock
No description available.
SectorHealthcare
IndustryBiotechnology
Employees317
CEODr. Arthur T. Sands M.D., Ph.D.
IPO DateJul 24, 2020
HeadquartersBrisbane, CA
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Arthur T. Sands M.D., Ph.D. | CEO, President & Director | 1962 |
| Mr. Johannes Van Houte | Chief Financial Officer | 1967 |
| Dr. Gwenn M. Hansen Ph.D. | Chief Scientific Officer | 1971 |
| Dr. Christine Ring J.D., Ph.D. | Chief Legal Officer, Secretary & Chief Compliance Officer | 1965 |
| Dr. John Kuriyan Ph.D. | Founder & Member of Scientific Advisory Board | — |
| Dr. Arthur Weiss M.D., Ph.D. | Founder & Member of Scientific Advisory Board | — |
| Rita Kwong | Senior Accounting Manager | — |
| Dr. Pasit Phiasivongsa Ph.D. | Chief Technical Officer | — |
| Mr. Wesley Burwell | Chief Human Resources Officer | — |
| Dr. Jason Kantor Ph.D. | Chief Business Officer | — |
Fundamentals
Valuation
Market cap$2.64B
Price-to-sales ratio71.98
Price-to-book value6.57
Price-earnings ratio-7.80
Return on Equity-64.00%
Return on SalesN/A
Return on AssetsN/A
PEG ratioN/A
Earnings Per Share
Earnings Per Share$-3.46
Income Statement
Average volume1,248,521
EBITDA$-276.02M
1 year high (52w)$28.23
1 year low (52w)$8.20
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A



